Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:2.3.1.21 (
CPT
)
4,580
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
1. The hypotensive effects of glyceryl trinitrate (
GTN
, 0.5 mg kg-1) but not of 3-morpholino-sydnonimine (SIN-1, 0.125 mg kg-1) in anaesthetized rats were attenuated following a seven day (using a q.i.d. dosing schedule) oral treatment with isosorbide-5-mononitrate (IS-5-MN; 5 mg kg-1) indicative of the induction of tolerance to
GTN
but not to SIN-1. The hypotensive effects of
GTN
did not decline when the sulphydryl (SH) containing angiotensin converting enzyme inhibitor (ACE-1), captopril (
CPT
, 5 mg kg-1) or the structurally unrelated SH-containing, N-acetylcysteine (NAC, 10 mg kg-1) but not the non-SH-containing ACE-I, enalaprilat (ENA, 5 mg kg-1) were given together with IS-5-MN for the seven days treatment. 2. The attenuated hypotensive effects of
GTN
(0.5 mg kg-1) in rats treated with IS-5-MN were also restored when
CPT
(1 mg kg-1) or NAC (2.5 mg kg-1) but not ENA (1 mg kg-1) was administered intraperitoneally (i.p.) 30 min before
GTN
. Furthermore, in control rats,
CPT
or NAC but not ENA given i.p. 30 min before
GTN
, potentiated its haemodynamic effects. These effects were blocked by methylene blue (10 mg kg-1). At the same doses,
CPT
or NAC did not affect the hypotensive effects of SIN-1. 3. The reduced ability of cultured tolerant smooth muscle cells (SMC, 24 x 103 cells) or endothelial cells(EC, 40 x 103 cells) to potentiate the anti-platelet effects of
GTN
(44 microM) was restored by
CPT
or NAC but not by ENA or glutathione (all at 0.5 mM). Potentiation of the anti-platelet effects of tolerant SMC or EC by
CPT
or NAC was abolished by co-incubation with oxyhaemoglobin (Oxy-Hb, 10 microM)indicative of nitric oxide (NO) formation.4. When
GTN
(150-2400 microM) was incubated with
CPT
, NAC or glutathione but not ENA (all at 0.1 mM) for 30 min in Krebs buffer at 37 degrees C a concentration-dependent increase in nitrite (NO2-)formation was observed. 5. The antiplatelet effects of
GTN
(5.5-352 microM) were potentiated by co-incubation with
CPT
or NAC but not with ENA or glutathione (all at 0.5 mM). The concentration of
GTN
required to inhibit platelet aggregation by 50% (IC50) was 110 +/- 2 microM for
GTN
alone, 14 +/- 2 microM for
GTN
in the presence of NAC and 30 +/- 2 microM for
GTN
in the presence of
CPT
. The potentiation of the effects of
GTN
by
CPT
or NAC was inhibited by co-incubation with Oxy-Hb (10 microM). By themselves,
CPT
or NAC did not inhibit platelet aggregation.6. The ability of
CPT
to restore (a) the haemodynamic effects of
GTN
in tolerant rats and (b) the reduced capacity of tolerant SMC or EC to potentiate the anti-platelet effects of
GTN
is not related to its ACE inhibitory activity.7.
CPT
also potentiated the hypotensive effects of
GTN
in non-tolerant rats, and in vitro
CPT
released NO from
GTN
in the absence of a
GTN
to NO converting cell, so that it is unlikely that reversal of tolerance by
CPT
is due to the replenishment of intracellular thiols. Rather it can be explained by the ability of
CPT
to release NO from
GTN
in the extracellular space. This extracellular formation of NO from
GTN
by
CPT
would then compensate for the impaired enzymic biotransformation of
GTN
to NO that develops during tolerance as was originally proposed for NAC.
...
PMID:Release of nitric oxide from glyceryl trinitrate by captopril but not enalaprilat: in vitro and in vivo studies. 835 44
This study was designed to investigate the effect of angiotensin-converting enzyme (ACE) inhibitors with and without a sulfhydryl group on intracellular production of cGMP, forearm blood flow, and neurohormonal factors during continuous transdermal application of
nitroglycerin
in patients with chronic heart failure. Platelet cGMP level and forearm blood flow were measured before and 5 min after sublingual administration of
nitroglycerin
(
NTG
) in 20 patients with chronic heart failure during the following 4 phases: (1) baseline phase; (2)
NTG
phase (1 week after
NTG
tape 10 mg/day); (3)
CPT
phase (1 week after both captopril 37.5 mg/day and
NTG
tape 10 mg/day); and (4) ENL phase (1 week after both enalapril 5 mg/day and
NTG
tape 10 mg/day). The platelet GMP level before sublingual
NTG
and forearm blood flow were significantly higher during the 3 phases with
NTG
tape than during the control phase. The percent increases in platelet cGMP level and forearm blood flow after sublingual
NTG
were significantly lower during the
NTG
phase than during the baseline phase. In contrast, concomitant application of ACE inhibitors maintained the percent increase in platelet cGMP level and forearm blood flow. These results indicate that concomitant therapy with ACE inhibitors may be helpful in preventing the attenuation of intracellular cGMP production in patients with chronic heart failure during continuous transdermal application of
NTG
.
...
PMID:Preventive effects of angiotensin-converting enzyme inhibitors on nitrate tolerance during continuous transdermal application of nitroglycerin in patients with chronic heart failure. 962 3
This study evaluated the effects of supplementation of carnitine and antioxidants on lipids, carnitine concentrations, and exercise endurance time in both trained and untrained rats as compared to non-supplemented rats. Thirty-two male SD rats, age 7 wk were divided into four groups according to exercise training and modified AIN-76 diets: NTNS (non-trained non-supplemented),
NTS
(non-trained supplemented), LTNS (long-trained non-supplemented) and LTS (long-trained supplemented). The trained rats were run on a treadmill for 60 min per day (10(0) incline, 20 m/min for 8 wk). Carnitine (0.5%/diet) and vitamin E (0.5 mg/g b.w.) were supplemented in rat diets and vitamin C (0.5 mg/g b.w.) and melatonin (1 microg/g b.w.) were administered into the stomachs of the rats. LTNS and LTS rats had significantly lower serum total lipid, triglyceride, total cholesterol and liver triglycerides, but had higher serum HDL-cholesterol. There were no changes in exercise endurance time by supplementation in untrained animals, however endurance times were longer in LTS animals than in LTNS. The supplementation and training tended to increase
carnitine palmitoyltransferase
(
CPT
-I) activities, although the differences were not statistically significant. Likewise,
CPT
-I mRNA levels were higher in both supplemented and exercise trained rats. These results suggest that supplementation of carnitine and antioxidants may improve lipid profiles and exercise ability in exercise-trained rats.
...
PMID:Exercise training and supplementation with carnitine and antioxidants increases carnitine stores, triglyceride utilization, and endurance in exercising rats. 1575 94